Trial Profile

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab/pembrolizumab (Primary) ; Lenvatinib (Primary) ; MK-4830 (Primary) ; Pembrolizumab/Quavonlimab (Primary)
Indications Small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms KEYNOTE-B98
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

27 May 2026 Status changed from recruiting to active, no longer recruiting.
19 Mar 2026 Planned primary completion date changed from 20 May 2026 to 10 Dec 2029.
10 Nov 2024 Planned End Date changed from 19 Nov 2029 to 10 Dec 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com